Loading...
Loading...
OPT| Name | Value |
|---|---|
| Revenues | 90.4M |
| Cost of Revenue | 0.2M |
| Gross Profit | 90.2M |
| Operating Expense | -78,654.4M |
| Operating I/L | -99,084.2M |
| Other Income/Expense | -0.1M |
| Interest Income | 0.0M |
| Pretax | -99,084.3M |
| Income Tax Expense | -6,293.0M |
| Net Income/Loss | -92,791.3M |
Opthea Limited is a clinical stage biopharmaceutical company based in Australia, specializing in the development and commercialization of therapies for eye diseases. The company's primary focus is on the development of novel therapies targeting Vascular Endothelial Growth Factors (VEGF) for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset, OPT 302, is a soluble form of VEGFR 3 in clinical development for wet neovascular age-related macular degeneration and diabetic macular edema. Opthea Limited also develops first-in-class VEGF C/D inhibitors for the treatment of wet neovascular AMD and other retinal diseases.
